FOP

News

FDA greenlights Regeneron drug for rare bone disease

Regeneron's Pasatru will be the second FDA-approved treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder.

News

FDA starts review of Regeneron's drug for rare disease FOP

Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?

News

Regeneron drug on track to be second FOP treatment

There is only one approved drug for ultra-rare disease FOP on the market, but Regeneron is hoping to add a second.

News

FDA sets new decision date for Ipsen’s FOP therapy

US agency sets 23rd August deadline for palovarotene review as Ipsen files more clinical data.

News

Ipsen adds Blueprint's FOP rare disease drug to pipeline for...

Ipsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a licence to develop and market a drug for the rare disease fibrodysplasia ossifican

FDA greenlights Regeneron drug for rare bone disease

FDA starts review of Regeneron's drug for rare disease FOP

Regeneron drug on track to be second FOP treatment

FDA sets new decision date for Ipsen’s FOP therapy

Ipsen adds Blueprint's FOP rare disease drug to pipeline for...

J&J scores EU approval for Tecvayli combo in second line

Discover a new era of healthcare panel engagement: Grounded ...

FOP

Editor's Picks